Mối liên hệ giữa cholesterol huyết tương và việc sử dụng thuốc hạ cholesterol với các hormone steroid giới tính trong huyết tương ở nam giới trong nghiên cứu NHANES III

Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5(12):930–942 Solomon KR, Freeman MR (2008) Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 19(4):113–121 Nelson WG (2007) Prostate cancer prevention. Curr Opin Urol 17(3):157–167 Hall SA, Page ST, Travison TG et al (2007) Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev 16(8):1587–1594 Farnsworth WH, Hoeg JM, Maher M et al (1987) Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin. J Clin Endocrinol Metab 65(3):546–550 Mastroberardino G, Costa C, Gavelli MS et al (1989) Plasma cortisol and testosterone in hypercholesterolaemia treated with clofibrate and lovastatin. J Int Med Res 17(4):388–394 Jay RH, Sturley RH, Stirling C et al (1991) Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Clin Pharmacol 32(4):417–422 Azzarito C, Boiardi L, Zini M et al (1992) Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients. Metabolism 41(2):148–153 Purvis K, Tollefsrud A, Rui H et al (1992) Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Pharmacol 42(1):61–64 Dobs AS, Miller S, Neri G et al (2000) Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metabolism 49(1):115–121 Santini SA, Carrozza C, Lulli P et al (2003) Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia. J Atheroscler Thromb 10(3):160–164 Bohm M, Herrmann W, Wassmann S, Laufs U, Nickenig G (2004) Does statin therapy influence steroid hormone synthesis? Z Kardiol 93(1):43–48 Dobs AS, Schrott H, Davidson MH et al (2000) Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 49(9):1234–1238 Hyyppa MT, Kronholm E, Virtanen A, Leino A, Jula A (2003) Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology 28(2):181–194 Ormiston T, Wolkowitz OM, Reus VI, Johnson R, Manfredi F (2004) Hormonal changes with cholesterol reduction: a double-blind pilot study. J Clin Pharm Ther 29(1):71–73 Azzarito C, Boiardi L, Vergoni W, Zini M, Portioli I (1996) Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res 28(4):193–198 Dobs AS, Sarma PS, Schteingart D (1993) Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism 42(9):1146–1152 Heller RF, Miller NE, Lewis B et al (1981) Associations between sex hormones, thyroid hormones and lipoproteins. Clin Sci (Lond) 61(5):649–651 Heller RF, Wheeler MJ, Micallef J, Miller NE, Lewis B (1983) Relationship of high density lipoprotein cholesterol with total and free testosterone and sex hormone binding globulin. Acta Endocrinol (Copenh) 104(2):253–256 Dai WS, Gutai JP, Kuller LH et al (1984) Relation between plasma high-density lipoprotein cholesterol and sex hormone concentrations in men. Am J Cardiol 53(9):1259–1263 Hamalainen E, Adlercreutz H, Ehnholm C, Puska P (1986) Relationships of serum lipoproteins and apoproteins to sex hormones and to the binding capacity of sex hormone binding globulin in healthy Finnish men. Metabolism 35(6):535–541 Lichtenstein MJ, Yarnell JW, Elwood PC et al (1987) Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am J Epidemiol 126(4):647–657 Stefanick ML, Williams PT, Krauss RM et al (1987) Relationships of plasma estradiol, testosterone, and sex hormone-binding globulin with lipoproteins, apolipoproteins, and high density lipoprotein subfractions in men. J Clin Endocrinol Metab 64(4):723–729 Barrett-Connor E, Khaw KT (1988) Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78(3):539–545 Kiel DP, Baron JA, Plymate SR, Chute CG (1989) Sex hormones and lipoproteins in men. Am J Med 87(1):35–39 Nanjee MN, Rajput-Williams J, Samuel L, Wootton R, Miller NE (1989) Relationships of plasma lipoprotein concentrations to unbound, albumin-bound and sex hormone-binding globulin-bound fractions of gonadal steroids in men. Eur J Clin Invest 19(3):241–245 Freedman DS, O’Brien TR, Flanders WD, DeStefano F, Barboriak JJ (1991) Relation of serum testosterone levels to high density lipoprotein cholesterol and other characteristics in men. Arterioscler Thromb 11(2):307–315 Khaw KT, Barrett-Connor E (1991) Endogenous sex hormones, high density lipoprotein cholesterol, and other lipoprotein fractions in men. Arterioscler Thromb 11(3):489–494 Kato I, Nomura A, Stemmermann GN, Chyou PH (1992) Determinants of sex hormone levels in men as useful indices in hormone-related disorders. J Clin Epidemiol 45(12):1417–1421 Tchernof A, Labrie F, Belanger A et al (1997) Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis 133(2):235–244 Zmuda JM, Cauley JA, Kriska A et al (1997) Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol 146(8):609–617 Wranicz JK, Cygankiewicz I, Rosiak M et al (2005) The relationship between sex hormones and lipid profile in men with coronary artery disease. Int J Cardiol 101(1):105–110 Nordoy A, Aakvaag A, Thelle D (1979) Sex hormones and high density lipoproteins in healthy males. Atherosclerosis 34(4):431–436 Deutscher S, Bates MW, Caines MJ et al (1986) Determinants of lipid and lipoprotein level in elderly men. Atherosclerosis 60(3):221–229 Van Pottelbergh I, Braeckman L, De Bacquer D, De Backer G, Kaufman JM (2003) Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 166(1):95–102 Mendoza SG, Zerpa A, Carrasco H et al (1983) Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol, and lipolytic enzymes in men with premature myocardial infarction and angiographically assessed coronary occlusion. Artery 12(1):1–23 Haffner SM, Mykkanen L, Valdez RA, Katz MS (1993) Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 77(6):1610–1615 National Cholesterol Education Program (2001) Expert panel on detection evaluation, and treatment of high blood cholesterol in adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). NIH publication. The Program, Bethesda, MD Beers MH, Berkow R, Merck Research L (1999) The Merck manual of diagnosis and therapy. In: Anonymous (ed). Merck Research Laboratories, Whitehouse Station Rinaldi S, Geay A, Dechaud H et al (2002) Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):1065–1071 Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84(10):3666–3672 Gunter EW, Lewis BG, Koncikowski SM (1996) Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. Report. Centers for Disease Control and Prevention, Hyattsville, MD Chumlea WC, Guo SS, Kuczmarski RJ et al (2002) Body composition estimates from NHANES III bioelectrical impedance data. Int J Obes Relat Metab Disord 26(12):1596–1609 American Heart Association (2008) What your cholesterol levels mean. American Hearth Association Bernini GP, Brogi G, Argenio GF, Moretti A, Salvetti A (1998) Effects of long-term pravastatin treatment on spermatogenesis and on adrenal and testicular steroidogenesis in male hypercholesterolemic patients. J Endocrinol Invest 21(5):310–317 Segarra A, Chacon P, Vilardell M, Piera LL (1996) Prospective case control study to determine the effect of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure. Nephron 73(2):186–190 Travia D, Tosi F, Negri C et al (1995) Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J Clin Endocrinol Metab 80(3):836–840 Selvin E, Feinleib M, Zhang L et al (2007) Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 30(2):234–238 Shannon J, Tewoderos S, Garzotto M et al (2005) Statins and prostate cancer risk: a case–control study. Am J Epidemiol 162(4):318–325 Platz EA, Leitzmann MF, Visvanathan K et al (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98(24):1819–1825 Flick ED, Habel LA, Chan KA et al (2007) Statin use and risk of prostate cancer in the California Men’s Health Study cohort. Cancer Epidemiol Biomarkers Prev 16(11):2218–2225 Jacobs EJ, Rodriguez C, Bain EB et al (2007) Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 16(11):2213–2217 Murtola TJ, Tammela TL, Lahtela J, Auvinen A (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case–control study. Cancer Epidemiol Biomarkers Prev 16(11):2226–2232 Friedman GD, Flick ED, Udaltsova N et al (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf 17(1):27–36 Edwards JE, Moore RA (2003) Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 4:18